Background: The current study aimed to evaluate the efficacy of superselective high-dose cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with advanced cancer of the nasal cavity and paranasal sinuses.
Methods: Between October 1999 and December 2006, 47 patients were given superselective intra-arterial infusions of cisplatin (100-120 mg/m2 per week) with simultaneous intravenous infusions of thiosulfate to neutralize cisplatin toxicity and conventional external-beam radiotherapy (65-70 grays).
Results: There were 7 patients (14.9%) diagnosed with T3, 22 (46.8%) with T4a, and 18 (38.3%) with T4b disease. During the median follow-up period of 4.6 years, the 5-year local progression-free survival rate was 78.4% for all patients (n=47), 69.0% for patients with T4b disease (n=18), and 83.2% for patients with
Conclusions: Although a single institution experience, the results of the current study suggest that RADPLAT can cure the majority of patients with advanced cancer of the nasal cavity and paranasal sinuses, as well as preserve organs. Late adverse reactions should be monitored in future studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.24515 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Selective internal radiation therapy segmentectomy: A new minimally invasive curative option for primary liver malignancies?
World J Gastroenterol
May 2024
The Second Radiology Department, National and Kapodistrian University of Athens, Chaidari Athens 12461, Greece.
Transarterial radioembolization or selective internal radiation therapy (SIRT) has emerged as a minimally invasive approach for the treatment of tumors. This percutaneous technique involves the local, intra-arterial delivery of radioactive microspheres directly into the tumor. Historically employed as a palliative measure for liver malignancies, SIRT has gained traction over the past decade as a potential curative option, mirroring the increasing role of radiation segmentectomy.
View Article and Find Full Text PDFPost-treatment magnetic resonance imaging predicts outcomes of maxillary sinus cancer treatment using super-selective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy (RADPLAT).
Auris Nasus Larynx
August 2024
Department of Radiology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan.
Article Synopsis
- * The research involved 24 patients and found that those who experienced tumor recurrence had significantly lower tumor reduction rates after treatment compared to those who did not experience recurrence.
- * The authors concluded that MRI-measured tumor reduction rates could help identify patients at higher risk of cancer recurrence and suggest that early intervention, like salvage surgeries, might be beneficial for those with lower reduction rates.
Impact of Radiation Dose on Treatment of Maxillary Cancer With Superselective Intra-arterial Cisplatin With Radiotherapy.
Anticancer Res
June 2023
Department of Radiation Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Background/aim: Maxillary sinus cancer is a relatively rare disease, and treatment is still evolving. We compared the efficacy of superselective intra-arterial infusion of high-dose cisplatin (CDDP) with concomitant radiotherapy (RADPLAT) using three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) and analyzed the relationship between the total radiation dose and the treatment outcome in localized maxillary sinus cancer.
Patients And Methods: We reviewed the cases of 58 patients with localized maxillary sinus cancer treated with RADPLAT at our institution from March 2004 to November 2020.
Low efficiency of leucocyte plugging-based drug delivery to cancer in mice.
Drug Deliv Transl Res
June 2022
Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Im Neuenheimer Feld 365, 69120, Heidelberg, Germany.
Cells of the immune system were proposed for use as Trojan horse for tumour-specific drug delivery. The efficacy of such cell-based drug delivery depends on the site-specific cell homing. This present study was aimed to investigate the potential of leucocytes for intratumoural site-specific enrichment using a locoregional application route in experimental liver tumours.
View Article and Find Full Text PDFDose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212): Dose-finding phase.
Head Neck
March 2018
Division of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Article Synopsis
- - The study focuses on a trial for treating advanced maxillary sinus cancer by using high-dose cisplatin via a specific method while also applying radiotherapy.
- - During the dose-finding phase, researchers aimed to identify any serious side effects and establish how many treatment cycles of cisplatin patients should receive.
- - Out of 18 patients, most completed 7 treatment cycles, and the therapy was found to be safe and tolerable, establishing 7 cycles as the recommended approach for these cancer patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!